PT167

PT167 is a preclinical-stage small molecule therapeutic being developed by Palisades Therapeutics. It is designed as a dual modulator of the glucocorticoid receptor (GR) and the androgen receptor (AR), two nuclear receptors that are frequently implicated in the progression and treatment resistance of various cancers. By targeting both receptors simultaneously, PT167 aims to provide a more comprehensive approach to inhibiting hormonal signaling pathways that drive tumor growth, particularly in cases where resistance to standard-of-care hormonal therapies has developed. The drug is currently positioned for development within the field of oncology.